Associated Papers
VARIANTS OF THE FORMATION AND COURSE OF DRUG-RESISTANT EPILEPSY IN CHILDREN WITH GENETIC POLYMORPHISMS OF CYP2C9, CYP2C19, CYP3A4.
Tantsura LM et al.
Wiadomosci Lekarskie (warsaw, Poland : 1960), 2023
Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions.
Ahmed AF et al.
Journal of Personalized Medicine, 2021
Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase.
Wang H et al.
Chinese Journal of Integrative Medicine, 2018
The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study.
Gemmati D et al.
Plos One, 2016
Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Wolkanin-Bartnik J et al.
Pharmacogenetics and Genomics, 2013
Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
Lee S et al.
Journal of Clinical Pharmacology, 2012
Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.
Djaffar-Jureidini I et al.
Genetic Testing and Molecular Biomarkers, 2011
Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
Miyagata Y et al.
International Heart Journal, 2011
Perioperative genomic profiles using structure-specific oligonucleotide probes.
Hogan KJ et al.
Clinical Medicine & Research, 2009
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.
Gage BF et al.
Journal of Thrombosis and Thrombolysis, 2008
Genetic testing for pharmacogenetics and its clinical application in drug therapy.
Hiratsuka M et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2006
Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations.
Nakai K et al.
Life Sciences, 2005
A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
Sookoian S et al.
The American Journal of Gastroenterology, 2005
Pharmacogenetics of acenocoumarol pharmacodynamics.
Morin S et al.
Clinical Pharmacology and Therapeutics, 2004
Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH et al.
Pharmacogenetics, 2002
[Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
van der Weide J et al.
Nederlands Tijdschrift Voor Geneeskunde, 2001
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
Taube J et al.
Blood, 2000
Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green.
Hiratsuka M et al.
Molecular Genetics and Metabolism, 1999
Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian.
Inoue K et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 1998
Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K et al.
Pharmacogenetics, 1997
Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.
Wang SL et al.
Pharmacogenetics, 1995